Clinician and Institution Profile

Not-For-Profit Academic Community Hospital

West Virginia University Camden Clark Medical Center

Parkersburg, West Virginia

Type of Facility: Short Term Acute Care, Level III Trauma Center

Type of Control: Voluntary non-profit

Total Staffed Beds: 251

Total Patient Revenue: $1,364,334,530

Total Discharges: 13,408

Total Patient Days: 60,056

LungVision® Acquisition: 2021



Roshen Mathew, MD

Interventional Pulmonologist

West Virginia University (WVU) Camden Clark Medical Center

Parkersburg, West Virginia

LungVision® Trained: 2021

Background

Dr. Roshen Mathew is the only interventional pulmonologist in the Mid-Ohio region and, having successfully built a Thoracic Oncology Program at WVU Camden Clark, was interested in a navigational bronchoscopy technology to serve as cornerstone for building a Lung Nodule Program. He explored robotics but decided that LungVision’s combination of navigation and real-time imaging made more clinical and financial sense.

Major factors for acquisition included:

• Real-time imaging minimizes or eliminates CT-to-body divergence for greater navigational accuracy and biopsy precision
• Low-cost-per-case (when using optional LungVision® procedural kits) compared with other navigation technologies
• Small physical footprint

Acquired LungVision® in October, 2021.

Clinical and Financial Impact¹

Data provided by Roshen Mathew, MD

Takeaway

WVU Camden Clark Medical Center’s acquisition of LungVision® AI-driven image guidance enabled them to…

• Boost their diagnostic yield from 68% pre-LungVision to 88% with LungVision, a 20% increase
• Grow diagnostic bronchoscopy procedural volume by 243% primarily by providing Dr. Mathew the confidence to pursue biopsy of nodules – namely smaller and more peripheral nodules – that he previously would not have felt comfortable going after
• Looked at robotic bronchoscopy platforms but decided that LungVision® made more clinical and financial sense given that LungVision® cost at least $1,000 less per case and generates at least $1,000 higher contribution margin ($3,200 vs. $2,200) per case with a comparable diagnostic yield
• 20% increase in diagnostic yield results in an estimated 14 additional diagnosed lung patients and $266K in incremental downstream revenue for the hospital annually

Sources

^¹Incremental downstream revenue based on number of additional diagnosed patients from increase in 20% diagnostic yield, assumptions that 50% of additional diagnosed patients diagnosed with cancer, 28% private payor / 72% Medicare-Medicaid payor mix, with 35% undergoing radiation therapy, 15% undergoing lung resection, 50% undergoing chemotherapy, 80% undergoing PET scans, 100% undergoing additional CT scans, and 100% undergoing pulmonary function test reimbursed at the national average for the appropriate CPT code.